FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655644> ?p ?o ?g. }

• W4385655644 endingPage "e8251354" @default.
• W4385655644 startingPage "e8251354" @default.
• W4385655644 abstract "Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Primary CNS lymphoma (PCNSL) is a highly aggressive non-Hodgkin lymphoma that originates in the brain, cerebrospinal fluid, spinal cord, or eyes. Because the affected areas of the CNS differ from patient to patient, clinical signs and symptoms of the disease are variable, and diagnosis requires a high level of suspicion. Aims: We aim to report our data on the use of the R-MPV protocole (Rituximab, Methotrexate, Procarbazine, Vincristine) followed by a reduced dose whole-brain radiotherapy in the treatment of PCNSL in real word settings. Methods: This is a descriptive retrospective study conducted on 10 immunocompetent patients, at the clinical hematology department of the Ibn Sina teaching hospital in Rabat over 6 years (January 2017-September 2022). Results: In the cohort studied, the median age was 50 years [19 years – 78 years], with a M/F sex ratio of 0.6 [6 females – 4 males].The clinical examination found a deteriorated general condition in the majority of patients (50% of the patients had a PS score of 4, 20% had a PS score of 3). Four patients had a pyramidal syndrome, three a cerebellar syndrome, two had phasic disorders, one had a Parinaud’s syndrome and one had intracranial hypertension. Sus and sub-tentorial locations were the most common in imaging (30%). The anatomopathological study showed a diffuse large B cell lymphoma (DLBCL) non germinal centre type in 9 patients, and an NOS T cell lymphoma in one patient. The therapeutic protocol consisted in the administration of Rituximab for B cell lymphomas, associated to Methotrexate, Procarbazine and Vincristine (R-MPV), and MPV for T cell lymphoma. A reduced dose whole-brain radiotherapy (rdWBRT) consolidation and high dose Cytarabine was performed. Complete remission was achieved in 6 patients (2 after 5 R-MPV cycles and 4 after 7 cycles). The median follow-up was 15.7 months, and the overall survival (OS) was 50%. The overall response to treatment (OR) was 70%. Progression free survival (PFS) at 6 months was 60%, and at 12 months 50% (1 primary refractory patient, 1 relapse and 1 progression). The complications were mainly hematological toxicities, with 80% grade III-IV neutropenia and thrombopenia. Summary/Conclusion: Following our experience, an advanced age at diagnosis, low PS score and late diagnosis are poor prognosis factors. The R-MPV protocol associated to consolidation rdWBRT and Cytarabine was associated with high response rate and minimal neurotoxicity, even in elderly patients. Keywords: Radiotherapy, Non-Hodgkin’s lymphoma, CNS lymphoma" @default.
• W4385655644 created "2023-08-09" @default.
• W4385655644 creator A5002129299 @default.
• W4385655644 creator A5004417542 @default.
• W4385655644 creator A5022315009 @default.
• W4385655644 creator A5038395752 @default.
• W4385655644 creator A5058427280 @default.
• W4385655644 creator A5092612018 @default.
• W4385655644 creator A5092612019 @default.
• W4385655644 creator A5092612020 @default.
• W4385655644 creator A5092612021 @default.
• W4385655644 date "2023-08-01" @default.
• W4385655644 modified "2023-09-27" @default.
• W4385655644 title "PB2363: R-MPV FOLLOWED BY CONSOLIDATION REDUCED-DOSE WHOLE-BRAIN RADIOTHERAPY AND CYTARABINE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: REAL WORLD DATA" @default.
• W4385655644 doi "https://doi.org/10.1097/01.hs9.0000976168.82513.54" @default.
• W4385655644 hasPublicationYear "2023" @default.
• W4385655644 type Work @default.
• W4385655644 citedByCount "0" @default.
• W4385655644 crossrefType "journal-article" @default.
• W4385655644 hasAuthorship W4385655644A5002129299 @default.
• W4385655644 hasAuthorship W4385655644A5004417542 @default.
• W4385655644 hasAuthorship W4385655644A5022315009 @default.
• W4385655644 hasAuthorship W4385655644A5038395752 @default.
• W4385655644 hasAuthorship W4385655644A5058427280 @default.
• W4385655644 hasAuthorship W4385655644A5092612018 @default.
• W4385655644 hasAuthorship W4385655644A5092612019 @default.
• W4385655644 hasAuthorship W4385655644A5092612020 @default.
• W4385655644 hasAuthorship W4385655644A5092612021 @default.
• W4385655644 hasBestOaLocation W43856556441 @default.
• W4385655644 hasConcept C126322002 @default.
• W4385655644 hasConcept C143998085 @default.
• W4385655644 hasConcept C167135981 @default.
• W4385655644 hasConcept C187212893 @default.
• W4385655644 hasConcept C2776694085 @default.
• W4385655644 hasConcept C2776755627 @default.
• W4385655644 hasConcept C2778559949 @default.
• W4385655644 hasConcept C2779112685 @default.
• W4385655644 hasConcept C2779338263 @default.
• W4385655644 hasConcept C2779429289 @default.
• W4385655644 hasConcept C2780653079 @default.
• W4385655644 hasConcept C2781059491 @default.
• W4385655644 hasConcept C2781173314 @default.
• W4385655644 hasConcept C509974204 @default.
• W4385655644 hasConcept C71924100 @default.
• W4385655644 hasConceptScore W4385655644C126322002 @default.
• W4385655644 hasConceptScore W4385655644C143998085 @default.
• W4385655644 hasConceptScore W4385655644C167135981 @default.
• W4385655644 hasConceptScore W4385655644C187212893 @default.
• W4385655644 hasConceptScore W4385655644C2776694085 @default.
• W4385655644 hasConceptScore W4385655644C2776755627 @default.
• W4385655644 hasConceptScore W4385655644C2778559949 @default.
• W4385655644 hasConceptScore W4385655644C2779112685 @default.
• W4385655644 hasConceptScore W4385655644C2779338263 @default.
• W4385655644 hasConceptScore W4385655644C2779429289 @default.
• W4385655644 hasConceptScore W4385655644C2780653079 @default.
• W4385655644 hasConceptScore W4385655644C2781059491 @default.
• W4385655644 hasConceptScore W4385655644C2781173314 @default.
• W4385655644 hasConceptScore W4385655644C509974204 @default.
• W4385655644 hasConceptScore W4385655644C71924100 @default.
• W4385655644 hasIssue "S3" @default.
• W4385655644 hasLocation W43856556441 @default.
• W4385655644 hasLocation W43856556442 @default.
• W4385655644 hasOpenAccess W4385655644 @default.
• W4385655644 hasPrimaryLocation W43856556441 @default.
• W4385655644 hasRelatedWork W2108492034 @default.
• W4385655644 hasRelatedWork W2161973217 @default.
• W4385655644 hasRelatedWork W2318987646 @default.
• W4385655644 hasRelatedWork W2337800630 @default.
• W4385655644 hasRelatedWork W2530053495 @default.
• W4385655644 hasRelatedWork W2976764540 @default.
• W4385655644 hasRelatedWork W3024712659 @default.
• W4385655644 hasRelatedWork W3032199847 @default.
• W4385655644 hasRelatedWork W3212185513 @default.
• W4385655644 hasRelatedWork W4311277256 @default.
• W4385655644 hasVolume "7" @default.
• W4385655644 isParatext "false" @default.
• W4385655644 isRetracted "false" @default.
• W4385655644 workType "article" @default.